After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
